Please login to the form below

Not currently logged in
Email:
Password:

MSD submits sarcoma drug for US approval

MSD has asked the US Food and Drug Administration to consider its oral mTOR inhibitor, ridaforolimus, for approval in the treatment of sarcomas – a cancer of the body's connective tissue

MSD has asked the US Food and Drug Administration (FDA) to consider its oral mTOR inhibitor, ridaforolimus, for approval in the treatment of patients with metastatic soft tissue or bone sarcomas in patients who had a favourable response to chemotherapy.

The therapy has already been submitted to the European Medicines Agency (EMA) for approval.

Sarcomas are a group of cancers of connective tissue of the body for which there are currently limited treatment options.

MSD obtained full rights to ridaforolimus in May 2010 in an agreement with its initial developers, ARIAD Pharmaceuticals, for an upfront payment of $50m plus additional milestone payments.

ARIAD agreed to co-promote the drug in the US if it is approved.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics